Defendant Name: Allergan, Inc.

Defendant Type: Subsidiary of Public Company
Public Company Parent: Allergan plc
SIC Code: 2834
CUSIP: G0177J10

Initial Case Details

Legal Case Name In the Matter of Allergan, Inc.
First Document Date 17-Jan-2017
Initial Filing Format Administrative Action
File Number 3-17790
Allegation Type Issuer Reporting and Disclosure

Violations Alleged

Section 14(d) Exchange Act; Rule 14d-9 Exchange Act


First Resolution Date 17-Jan-2017
Headline Total Penalty and Disgorgement

See Related Documents

Related Documents:

34-79814 17-Jan-2017 Administrative Proceeding
Order Instituting Cease-and-Desist Proceedings Pursuant to Section 21C of the Securities Exchange Act of 1934, Making Findings, and Imposing a Cease-and-Desist Order
On January 17, 2017 the SEC instituted a settled order against Allergan, Inc. According to the SEC: Allergan failed "to comply with the disclosure requirements concerning merger and acquisition negotiations with third parties that it conducted in response to a tender offer."
2017-16 17-Jan-2017 Press Release--Administrative Proceeding
Allergan Paying $15 Million Penalty for Disclosure Failures During Merger Talks
On January 17, 2017 the SEC announced in a press release that Allergan Inc. "has agreed to admit securities law violations and pay a $15 million penalty for disclosure failures in the wake of a hostile takeover bid." According to the SEC: "Allergan failed to disclose in a timely manner its negotiations with potentially friendlier merger partners in the months following a tender offer from Valeant Pharmaceuticals International and co-bidders in June 2014."